Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset

NCT03541668 is registered in ClinicalTrials.gov with Tasly Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT03541668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03541668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset
Lead sponsor
Tasly Biopharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 18, 2018
Completion date
May 24, 2020
Enrollment
674 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischaemic stroke